Does the beta-blocker nebivolol increase coronary flow reserve?

Togni, Mario; Vigorito, Francesco; Windecker, Stephan; Abrecht, Linda; Wenaweser, Peter; Cook, Stephane; Billinger, Michael; Meier, Bernhard; Hess, Otto M (2007). Does the beta-blocker nebivolol increase coronary flow reserve? Cardiovascular drugs and therapy, 21(2), pp. 99-108. Branford, Conn.: Kluwer Academic Publishers-Plenum Publishers; http://www.springer-ny.com 10.1007/s10557-006-0494-7

[img]
Preview
Text
10557_2006_Article_494.pdf - Published Version
Available under License Publisher holds Copyright.

Download (254kB) | Preview

INTRODUCTION: Nebivolol, a highly selective beta1-adrenergic receptor-blocker, increases basal and stimulated endothelial nitric oxide (NO)-release. It is unknown, whether coronary perfusion is improved by the increase in NO availability. Therefore, we sought to evaluate the effect of nebivolol on coronary flow reserve (CFR) and collateral flow. METHODS: Doppler-flow wire derived coronary flow velocity measurements were obtained in ten controls and eight patients with coronary artery disease (CAD) at rest and after intracoronary nebivolol. CFR was defined as maximal flow during adenosine-induced hyperemia divided by resting flow. In the CAD group, collateral flow was determined after dilatation of a flow-limiting coronary stenosis. Collateral flow index (CFI) was defined as the ratio of flow velocity during balloon inflation divided by resting flow. RESULTS: CFR at rest was 3.0+/-0.6 in controls and 2.1+/-0.4 in CAD patients. After intracoronary doses of 0.1, 0.25, and 0.5 mg nebivolol, CFR increased to 3.4+/-0.7, 3.9+/-0.9, and 4.0+/-0.1 (p<0.01) in controls, and to 2.3+/-0.7, 2.6+/-0.9, and 2.6+/-0.5 (p<0.05) in CAD patients. CFI decreased significantly with intracoronary nebivolol and correlated to changes in heart rate (r=0.75, p<0.001) and rate-pressure product (r=0.59, p=0.001). DISCUSSION: Intracoronary nebivolol is associated with a significant increase in CFR due to reduction in resting flow (controls), or due to an increase in maximal coronary flow (CAD patients). CFI decreased with nebivolol parallel to the reduction in myocardial oxygen consumption.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Cardiology

UniBE Contributor:

Windecker, Stephan; Wenaweser, Peter Martin; Cook, Stéphane; Billinger, Michael; Meier, Bernhard and Hess, Otto

ISSN:

0920-3206

ISBN:

17235472

Publisher:

Kluwer Academic Publishers-Plenum Publishers; http://www.springer-ny.com

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:54

Last Modified:

26 Jun 2018 15:04

Publisher DOI:

10.1007/s10557-006-0494-7

PubMed ID:

17235472

Web of Science ID:

000247154500006

BORIS DOI:

10.7892/boris.23216

URI:

https://boris.unibe.ch/id/eprint/23216 (FactScience: 40612)

Actions (login required)

Edit item Edit item
Provide Feedback